Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)

August 5th, 2020|0 Comments

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

May 13th, 2020|0 Comments

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

May 5th, 2020|0 Comments

Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the US

April 19th, 2020|0 Comments

  • patient receiving dose of medication

Cycle Pharmaceuticals’ Supply Chain update

March 13th, 2020|0 Comments

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

December 18th, 2019|0 Comments

Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph

November 18th, 2019|0 Comments

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

October 31st, 2019|0 Comments

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

April 28th, 2019|0 Comments

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

November 22nd, 2018|0 Comments

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

November 19th, 2018|0 Comments

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

November 12th, 2018|0 Comments

FOLLOW US
WHY CYCLE PHARMA

We target market imbalance where we can better serve patient health needs by innovating drugs

More About Cycle